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Introduction
Members of the ErbB family of receptor tyrosine kinases, 
comprising  ErbB1  (epidermal  growth  factor  receptor 
[EGFR]),  ErbB2  (Her2/Neu),  ErbB3,  and  ErbB4,  have 
pathological functions in a wide range of tumors, as they 
activate a variety of signaling pathways inside tumor and 
stromal cells to sustain proliferation, survival, angiogene-
sis, invasion, and metastasis.
1-3 Signaling cascades that lie 
downstream  of  ErbB  activation  include  the  mitogen- 
activated protein (MAP) kinase and PI3K/Akt pathways.
4 
During normal development, ErbB signaling results from 
the  binding  of  individual  ErbB  receptors  with  cognate 
ligands  of  the  EGF  family,  which  comprises  epidermal 
growth factor (EGF), transforming growth factor–α (TGF-
α), amphiregulin (AREG), epigen (EPGN), heparin-binding 
EGF-like  growth  factor  (HB-EGF),  betacellulin  (BTC), 
epiregulin (EPR), and neuregulin 1 to 4 (NRG1-4). These 
ligands are highly redundant, have specific ErbB-binding 
patterns and affinities, and all except for the 4 NRG ligands 
bind and activate ErbB1/EGFR.
5
In a wide range of human carcinomas (breast, pancreas, 
colon, head and neck, lung, etc.), EGFR and/or HER2 are 
significantly overexpressed, usually following gene ampli-
fication.
6 Such gene amplification has been associated with 
a poor prognosis in a number of cancer types for both EGFR 
and HER2.
7 However, while a correlation exists between 
the HER2 overexpression status in breast tumors and their 
sensitivity to HER2 inhibitors, such a correlation has failed 
to materialize in clinical trials involving EGFR inhibitors,
8 
leaving a gap in our understanding of tumor dependency on 
EGFR signaling. In non–small cell lung cancer (NSCLC), 
the presence of mutations in the EGFR kinase domain is a 
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Abstract
Factors associated with tumor sensitivity to epidermal growth factor receptor (EGFR) inhibitors in the context of wild-type EGFR remain elusive. 
This study investigates the mechanistic basis of responsiveness to EGFR inhibitors in the RIP1-Tag2 (RT2) mouse model of pancreatic neuroendocrine 
tumorigenesis (PNET). Upon treatment of RT2 mice with EGFR inhibitors, PNET tumors harboring wild-type, nonamplified alleles of Egfr grow at a 
markedly reduced rate and display a significant increase in tumor cell apoptosis, as well as reduced neovascularization. The authors identify Tgf-α and 
Hb-egf as key limiting mediators of separable pathological functions of Egfr in neuroendocrine tumor progression: Tgf-αα mutant tumors present with an 
elevated apoptotic index, whereas Hb-egf mutant lesions exhibit decreased angiogenic switching and neovascularization. This study not only associates 
Tgf-αα and Hb-egf expression with wild-type Egfr oncogenicity but also ascribes the proangiogenic activity of Egfr in this tumor model to a novel 
mesenchymal Hb-egf/Egfr signaling axis, whereby endothelial and pericyte-derived Hb-egf activates Egfr specifically in tumor-associated perivascular cells, 
leading to increased pericyte coverage of the tumor endothelium and enhanced angiogenesis.
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striking  predictor  of  tumor  sensitivity  to  EGFR  inhibi-
tors.
9-11 In NSCLC patients, the frequency of EGFR muta-
tions  (~9%  in  non-Japanese  patients
8)  is  remarkably 
correlated  with  the  objective  clinical  response  (tumor 
shrinkage)  rate  observed  in  NSCLC  patient  cohorts 
(~10%),
12 but it fails to account for the additional 30% of 
patients  who  present  with  stable  disease  following  anti-
EGFR treatment.
12 In addition, data from two studies of 
NSCLC patients show that no EGFR mutation was detected 
in tumor samples from 6 of 31 patients presenting an objec-
tive clinical response to EGFR inhibitors.
9,11 In metastatic 
colorectal cancer (mCRC) patients, the objective response 
rate to anti-EGFR antibody therapy of ~10% and the addi-
tional stable disease rate of ~30% cannot be predicted by 
chromosomal amplification of the EGFR locus observed in 
~2% of mCRC patients
13 and do not correlate with muta-
tions in EGFR, observed in only 0.34% of CRC samples.
14-16 
These results collectively indicate that many patients with 
wild-type EGFR alleles respond to EGFR inhibitors, and 
research is ongoing regarding the factors that contribute to 
EGFR inhibitor tumor sensitivity, other than mutations in 
EGFR in NSCLC
12 or chromosomal amplification of EGFR 
in colon cancer.
17
It has long been known that ligands of the EGF family 
are overexpressed in a significant subset of solid tumors 
and are prognostic factors of poor disease outcome,
18 sug-
gesting that tumor progression may depend on the presence 
of these ligands. Given that in vivo overexpression of Tgf-α 
in mice is clearly pro-oncogenic in the context of wild-type 
Egfr, leading to pancreatic hyperplasia and mammary epi-
thelial carcinogenesis,
19,20 expression of EGF family ligands 
may be one of the keys to our understanding of tumor sen-
sitivity to EGFR inhibitors. A preclinical study of subcuta-
neously transplanted human lung cancer cells supports this 
hypothesis, as TGF-α mediates tumor sensitivity to EGFR 
inhibitors in this system.
21
The RIP1-Tag2 (RT2) mouse model of pancreatic neuro-
endocrine tumors (PNET)
22 provides a well-studied in vivo 
platform in which to investigate the potential role of Egfr 
signaling in the stepwise progression of neoplastic lesions 
toward malignancy. The purification of betacellulin, a pan-
ErbB EGF family ligand, from the conditioned media of 
RT2-derived cancer cells
23 and the fact that a majority of 
human  neuroendocrine  tumors  express  phosphorylated 
Egfr
24 suggested a possible involvement of ErbB signaling 
in  multistage  pancreatic  neuroendocrine  carcinogenesis. 
Neoplastic lesions in RT2 mice progress through several 
phenotypic transitions that are stereotypic to many forms of 
human carcinogenesis. About half of the 400 normal pan-
creatic islets become hyperplastic/dysplastic and begin to 
proliferate upon expression of the SV40 T antigen (Tag) 
oncogene. About 20% of the hyperproliferative islet lesions 
undergo angiogenic switching, and half of these angiogenic 
islets progress to the tumor stage, often beginning as encap-
sulated  adenomas  that  progress  to  malignant  invasive 
carcinomas.
25
In this study, we demonstrate that RT2 PNET tumors 
engage the Egfr receptor in vivo, and while the tumors do 
not harbor chromosomal amplifications or mutations of the 
Egfr locus, they are nonetheless sensitive to pharmacologi-
cal or genetic Egfr inactivation. Upon exposure to EGFR 
inhibitors, PNET tumors grow at a much reduced rate and 
present with a decreased neovasculature and an elevated 
apoptotic index. We ascribe the activation of two distinct 
pools of Egfr in PNET tumors (the first in cancer cells and 
the second in tumor-associated pericytes) to 2 EGF family 
ligands, Tgf-α and Hb-egf, which respectively mediate the 
antiapoptotic and proangiogenic activities of Egfr, reveal-
ing  dual  roles  for  Egfr  signaling  in  this  tumorigenesis 
pathway.
Results
Wild-type Egfr signaling contributes to the growth and neo-
vascularization of PNET tumors. To probe the potential role of 
EGFR signaling in PNET tumors of RT2 transgenic mice, 
we surveyed the expression profile of the ErbB family of 
receptors in each of the discrete stages of this tumorigenesis 
pathway. After isolating total RNA from pancreatic islets at 
different stages of disease progression (normal pancreatic 
islets,  hyperplastic  islets,  angiogenic  islets,  and  islet 
tumors), we measured the expression levels of Egfr, Erbb2, 
Erbb3, and Erbb4 by quantitative real-time PCR (RT-PCR; 
Fig. 1A). Among Erbb receptors, Erbb2 and Erbb4 mRNA 
levels decreased with malignant progression and became 
barely detectable at the tumor stage. By contrast, Egfr and 
Erbb3 were detected at all stages of tumor development, 
and the Egfr mRNA was the most prominently detected of 
the 4 Erbbs throughout the multistep pathway (Fig. 1A). We 
then surveyed the activation of Egfr and the concurrent acti-
vation  of  two  signaling  circuits  that  lie  downstream  of 
EGFR  activation:  mitogen-activated  protein  kinase 
(MAPK) and PI3K/Akt. Western blot analysis of protein 
extracts from the different RT2 stages revealed that Egfr 
phosphorylation increases during RT2 progression, as does 
Akt phosphorylation, reflecting the coincident activation of 
Egfr  and  the  PI3K  pathway  (Fig.  1B).  Surprisingly, 
pMek1/2, which indicates activation of the MAPK path-
way, decreases steadily as RT2 lesions progress to malig-
nancy (Fig. 1B). To assess the functional contribution of 
Egfr to Akt phosphorylation, we treated 14-week-old RT2 
mice harboring advanced tumors with the EGFR inhibitor 
erlotinib  for  4  days.  Following  erlotinib  treatment,  the 
phosphorylation  of  Egfr  and Akt  in  tumor  extracts  was   
significantly reduced, indicating that Egfr activation contrib-
utes to Akt activation in these neoplastic lesions (Fig. 1C).Parallel activation of Egfr in cancer cells and pericytes / Nolan-Stevaux et al.  127
To investigate the possibility that Egfr activation was 
involved in the pathobiology of these PNET tumors, we 
treated cohorts of RT2 mice with different EGFR inhibitors 
(gefitinib, CI-1033, erlotinib) for 3 to 4 weeks beginning at 
11 to 12 weeks of age, a stage at which small adenoma are 
already present. Gefitinib and erlotinib are specific inhibi-
tors of EGFR,
26 whereas CI-1033, in addition to blocking 
EGFR, also inhibits the kinase activity of Erbb2 and Erbb4 
(Erbb3  does  not  possess  intrinsic  kinase  activity).
27 All 
treated cohorts of RT2 mice displayed a striking 50% to 
60% decrease in tumor burden (average total tumor volume 
per mouse) compared to vehicle-treated cohorts (Figs. 1 
D-F). The growth of these tumors was not halted but was 
significantly  slowed  upon  EGFR  inhibitor  treatment,  as 
shown in Figure 1F (compare vehicle treated at week 12 to 
erlotinib treated at week 16). Moreover, we found that treat-
ing 6-week-old RT2 mice with EGFR inhibitors (erlotinib 
or CI-1033) for 3 weeks resulted in a ~30% decrease in the 
number  of  islets  undergoing  angiogenic  switching  (Fig. 
1G), indicating that Egfr activity also contributes to this 
pathological  transition.  A  detailed  phenotypic  analysis 
revealed that treated tumors displayed no decrease in tumor 
cell proliferation (assayed by BrdU incorporation) as com-
pared to vehicle-treated tumors (Figs. 2 A-C) but had a 
Figure 1. Egfr activity contributes to RT2 tumor growth and angiogenic switching. (A) Relative expression quantified by real-time quantitative PCR of 
Erbb family members in cDNAs derived from total RNA extracts of successive stages of pancreatic neuroendocrine tumorigenesis from RIP1-Tag2 (RT2) 
transgenic mice (NI = normal islets; HI = hyperplastic islets; AI = angiogenic islets; IT = islet tumors). Levels of mRNAs are expressed as a percentage of 
the mGus control mRNA. (B) Western blot analysis of protein extracts from successive stages of RT2-derived lesions. (C) Western blot analysis of protein 
extracts from RT2-derived tumors 4 h after treatment with a vehicle solution or erlotinib (80 mg/kg). (D-F) Comparison of the average tumor burden 
of RT2 mice treated daily with a control solution (vehicle) or with (D) gefitinib (80 mg/kg), (E) CI-1033 (80 mg/kg), both from 11.5 to 14.5 weeks of age, 
or with (F) erlotinib (80 mg/kg), from 12 to 16 weeks of age with an additional vehicle-treated time point at 14 weeks. (G) Comparison of the average 
number of hemorrhagic angiogenic islets per pancreas of RT2 mice treated daily with a vehicle solution or with erlotinib (80 mg/kg) or CI-1033 (80 mg/
kg) from 6 to 9 weeks of age. (N = number of animals per treatment group). *P < 0.01.128    Genes & Cancer / vol 1 no 2 (2010)
markedly elevated apoptotic index (assayed by TdT-mediated 
dUTP-biotin nick end-labeling [TUNEL] staining) (Figs. 2 
D-F) and significantly decreased vascular density (assayed 
by counting FITC-lectin perfused vessels) (Figs. 2 G-I).
In  previous  studies  of  human  patients,  sensitivity  to 
EGFR inhibitors was correlated with activating mutations 
in the kinase domain of EGFR or with genomic amplifica-
tion of the EGFR locus. We know from previous studies of 
chromosomal  gains  and  losses  in  RT2  tumors  that  the 
mouse Egfr locus (chromosome 11-9.0 cM) is not amplified 
in RT2 malignancies.
28 To determine whether mutations in 
the kinase domain could account for the sensitivity of these 
PNET tumors to EGFR inhibitors, we sequenced the kinase 
domain of Egfr from 6 independent tumors. As shown in 
Supplementary Figure S1, we detected no mutation of Egfr 
in these tumor DNA samples, although a silent polymor-
phism was found to be present in the BL6/J background of 
RT2 mice.
Figure 2. Phenotype of epidermal growth factor receptor (EGFR) inhibitor-treated pancreatic neuroendocrine tumorigenesis (PNET) tumors from 
RT2 mice. (A) Average percentage of dividing tumor cells (BrdU-positive) in vehicle- or erlotinib-treated mice following 1 week of treatment. (B-C) 
Representative micrographs of tumors from (B) vehicle- or (C) erlotinib-treated RT2 mice stained with an anti-BrdU antibody (200x). (D) Average 
percentage of apoptotic tumor cells (TdT-mediated dUTP-biotin nick end-labeling [TUNEL] positive) in tumors from vehicle- or erlotinib-treated mice 
following 1 week of treatment. (E-F) Representative micrographs of (E) vehicle- or (F) erlotinib-treated tumors stained with an anti-digoxigenin antibody 
following Tunel procedure (200x). (G) Average number of blood vessels per field (FITC-positive continuous segments) in vehicle- or erlotinib-treated mice 
following 1 week of treatment. (H-I) Representative micrographs of (H) vehicle- or (I) erlotinib-treated tumors that were collected following systemic 
perfusion with FITC-lectin to visualize the functional tumor vasculature (green); counterstaining with DAPI reveals the cellularity (blue) (200x). The panels 
are representative of 2 fields of tissue sections obtained from tumors in at least 4 treated RT2 mice. (N = number of independent tumors analyzed per 
treatment group). *P < 0.001. **P < 0.02.Parallel activation of Egfr in cancer cells and pericytes / Nolan-Stevaux et al.  129
Thus, Egfr is increasingly phosphorylated as pancreatic 
islet neoplasias grow and progress toward a malignant state. 
Egfr contributes significantly to the downstream activation 
of Akt, a key cellular survival pathway, and Egfr activation 
promotes tumor growth, angiogenic switching, cancer cell 
survival, and tumor angiogenesis, as revealed by its phar-
macological inhibition. Tumor sensitivity to EGFR inhibi-
tors is observed despite the fact that these tumors harbor no 
mutation or amplification of the Egfr locus; moreover, com-
parable  phenotypes  observed  following  treatment  with 
EGFR-specific  inhibitors  (gefitinib,  erlotinib)  or  a  pan-
Erbb inhibitor (CI-1033) indicate that EGFR is likely the 
functionally predominant Erbb tyrosine kinase in this model 
of PNET tumorigenesis.
Expression of Tgf-α and Hb-egf correlates with phenotypic 
transitions of PNET lesions. Because wild-type Egfr is increas-
ingly phosphorylated as RT2 lesions progress toward malig-
nancy, we searched for candidate ligands that might mediate 
the increasing activation of Egfr by surveying the expression 
of all known genes of the EGF ligand family by quantitative 
RT-PCR during PNET tumorigenesis (Fig. 3A). This survey 
pointed toward two candidates, Tgf-α and Hb-egf, which 
were expressed at appreciably higher levels than the other 
ligand-encoding genes and also showed increased expres-
sion  during  one  or  more  progressive  disease  stages. As 
shown in Figure 3A, levels of Tgf-α transcripts increase 6.5-
fold between normal islets and the islet tumor stage, whereas 
Hb-egf  expression  increases  ~2-fold  at  the  hyperplastic 
stage and remains readily detectable at later stages of RT2. 
Interestingly, Btc, the EGF family ligand that was discov-
ered in the conditioned medium of a RT2-derived cell line,
23 
was barely detectable in RT2 tumors, suggesting it is not a 
key in vivo mediator of Egfr activation in RT2. This was 
confirmed by crossbreeding RT2 mice into a homozygous 
Btc-null background
29: mice lacking Btc did not present any 
defect in tumor growth or angiogenic switching (data not 
shown). The other ligands, including Nrg-1, -2a, -2b, 3, and 
4, were expressed at very low levels or their expression lev-
els decreased during tumor progression (data not shown) 
and were not considered further.
Next,  we  analyzed  the  protein  expression  profile  of   
Tgf-α and Hb-egf, to visualize if these signaling peptides 
were processed into membrane-bound proforms or soluble 
forms,  which  are  both  bioactive.
30,31 The  low  molecular 
weight  soluble  form  of  Tgf-α  initially  increases  at  the 
hyperplastic stage of RT2 progression before disappearing 
in later stages, whereas the membrane-bound proform of 
Tgf-α capable of stimulating EGFR phosphorylation,
32,33 
proliferation,
34  and  transformation
35  in  adjacent  cells 
increases significantly at the angiogenic and tumor stages 
(>15-fold) of RT2 (Fig. 3B). In parallel, bioactive forms of 
Hb-egf (the 27-kD membrane-bound form and the 22-kD 
soluble  form)  increased  dramatically  at  the  angiogenic 
(>30-fold) and tumor stages (Fig. 3C).
Figure 3. Dynamic expression and processing of Tgf-α and Hb-egf during multistep pancreatic neuroendocrine tumorigenesis (PNET). (A) Relative 
expression of Egf family members in cDNAs prepared from total RNA extracts of successive stages of neoplastic progression (NI = normal islets; HI = 
hyperplastic islets; AI = angiogenic islets; IT = islet tumors). Levels of mRNAs are expressed as a percentage of the mGus control mRNA. (B) Western blot 
analysis of the various forms of Tgf-α polypeptides in total protein extracts from successive stages of disease progression. (C) Analogous Western blot 
analysis of the various forms of Hb-egf polypeptides in total protein extracts from the successive disease stages.130    Genes & Cancer / vol 1 no 2 (2010)
Thus, the dynamic expression of bioactive Tgf-α and 
Hb-egf  during  RT2  progression  was  suggestive  of  their 
involvement at the angiogenic and tumor stages of RT2 
carcinogenesis.
Tgf-α enhances cancer cell survival and is required for the 
growth  of  PNET  tumors  in  RT2  mice.  Given  the  evident 
upregulation  of  Tgf-α  during  the  PNET  tumorigenesis 
pathway, we sought to assess its possible functional contri-
bution  by  crossbreeding  the  RT2  transgenic  mice  with 
waved-1 mutant mice harboring a mutant loss-of-function 
allele of Tgf-α that is characterized by the near extinction 
of Tgf-α expression.
36,37 We surveyed the key parameters 
of tumor progression in cohorts of compound RT2: Tgf-α 
mutant mice of different ages, aiming to identify stages of 
disease progression that were affected by the loss of Tgf-α 
function. No difference was observed between wild-type 
and waved-1 animals in the proportion of hyperprolifera-
tive islets at 7.5 weeks (data not shown) or in the number 
of hemorrhagic angiogenic islet dysplasias at 9 weeks (Fig. 
4A). In contrast, average tumor burden was decreased in 
Tgf-α mutant mice (Fig. 4B) but not the average tumor 
number per mouse (Fig. 4C), indicating that Tgf-α enhances 
PNET  tumor  growth  but  not  tumor  initiation  from  the 
abundant pool of angiogenic islet precursor lesions. We 
confirmed by Western blot analysis that Tgf-α expression 
was abolished in waved-1 tumor extracts (Fig. 4D). Then 
we dispelled the possibility that the decreased pathology 
observed in RT2, wa-1/wa-1 mice could be due to preexist-
ing developmental defects in pancreatic islets of homozy-
gous waved-1 mutants by comparing the morphology of 
pancreatic  islets  (Supplementary  Figs.  2 A  and  B),  the 
expression of insulin in pancreatic islets (Supplementary 
Figs. 2 C and D), and endocrine pancreatic function (via a 
glucose tolerance test) (Supplementary Fig. 2E) of wild-
type versus waved-1 homozygous animals. As no signifi-
cant difference was detected in any of these parameters or 
in  islet  size  (data  not  shown),  we  concluded  that  the 
decreased  tumor  growth  observed  in  RT2,  wa-1/wa-1 
mutant mice did not result from a preexisting defect in 
endocrine  pancreatic  development  but  rather  stemmed 
from the functional contribution of Tgf-α to neuroendo-
crine tumor growth.
To assess the pathological function of Tgf-α in PNET 
tumors, we compared the proliferation index (assayed by 
phospho-Histone H3 staining—Fig. 4E), blood vessel den-
sity (assayed by measuring areas of Meca-32 staining— 
Fig.  4F),  and  apoptotic  index  (assayed  by  TUNEL 
staining—Fig.  4G)  of  wild-type  versus  waved-1  mutant 
tumors. We found that Tgf-α mutant tumors had elevated 
numbers of TUNEL-positive apoptotic cells compared with 
Tgf-α competent tumors (see representative panels—Fig. 4 
H-I), whereas there were no changes in proliferation rate or 
tumor  vascularity,  indicating  that  Tgf-α  functioned  to 
enhance tumor growth by limiting the rate of cancer cell 
apoptosis.
Hb-egf contributes to angiogenic switching and tumor neo-
vascularization. Given the elevated level of Hb-egf protein 
expression observed at the angiogenic and tumor stages of 
disease progression, we sought to identify the functional 
contribution of this ligand to the pathology of both prema-
lignant  and  tumor  stages.  We  bred  Hb-egf  null  mutant 
mice
29  to  RT2  transgenic  animals,  following  extensive 
back-crossing  of  the  Hb-egf  allele  into  the  C3HeB/FeJ 
genetic  background  (see  Methods)  because  homozygous 
Hb-egf mutants were nonviable in a pure C57BL/6J back-
ground. We assessed the same histopathological parameters 
of  tumor  progression  described  previously,  comparing 
cohorts of wild-type RT2 versus RT2, Hb-egf−/− littermates 
at different stages of cancer progression. We found no dif-
ference  in  the  proportion  of  BrdU-positive  islets  at  7.5 
weeks of age (data not shown), indicating that Hb-egf is not 
involved  in  the  onset  of  hyperproliferation  that  leads  to 
hyperplastic/dysplastic (preangiogenic) islets. In contrast, 
the  absence  of  Hb-egf  affected  the  angiogenic  islet  and 
tumor phenotypes. There was a ~30% decrease in the aver-
age  number  of  angiogenic  islets  in  9-week-old  Hb-egf 
mutant mice (Fig. 5A), at the peak of angiogenic switching 
but before the formation of solid tumors. And in 14.5-week-
old RT2, Hb-egf−/− mutant mice, we observed both a ~30% 
decrease in the average total tumor load per mouse (tumor 
burden—Fig. 5B) and a similar decrease in the average 
number of tumors per mouse (Fig. 5C).
We performed a Western blot analysis of protein extracts 
from wild-type and Hb-egf mutant tumors and confirmed the 
depletion of the Hb-egf ligand in Hb-egf mutant tumors (Fig. 
5D). We also verified that normal endocrine pancreatic devel-
opment was normal in Hb-egf mutant mice to rule out the pos-
sibility that the observed tumor phenotypes could be secondary 
consequences of developmental defects occurring before the 
onset of tumorigenesis. The histology and morphology of 
islets  of  Langerhans  were  normal  in  Hb-egf  mutant  mice 
(Supplementary Figs. S3 A and B), the pattern of insulin stain-
ing was not affected in Hb-egf mutant pancreas (Supplemen-
tary Figs. S3 C and D), and Hb-egf mutant mice presented no 
defects  in  glucose  tolerance,  indicating  normal  pancreatic 
β-cells function (Supplementary Fig. S3E).
Having established that Hb-egf was not involved in nor-
mal islet development or homeostasis, we proceeded to ana-
lyze the phenotype of Hb-egf mutant tumors in detail. There 
was no evident difference in the proliferation and apoptotic 
indices between wild-type and Hb-egf mutant tumors (Figs. 
5 E-F). There was, however, a 28% decrease in vessel den-
sity in Hb-egf mutant tumors (Fig. 5G—representative pan-
els Figs. 5H-I). Together, these analyses indicate that Hb-egf is 
involved in regulating angiogenic switching in premalignant 
lesions and the growth and/or maintenance of the angiogenic Parallel activation of Egfr in cancer cells and pericytes / Nolan-Stevaux et al.  131
vasculature in PNET tumors. The fact that (1) Hb-egf mutant 
tumors did not display defects in apoptosis or proliferation, 
(2) the number of tumors per Hb-egf mutant mouse was 
decreased as compared to wt mice, but (3) not the average 
size of individual tumors across the 2 mouse cohorts (10.22 
mm
3 in wt mice—N = 228 vs 9.69 mm
3 in Hb-egf mutant 
mice—N  =  143;  P  =  0.2283)  collectively  indicates  that 
defects observed at the tumor stage may be secondary to 
Figure 4. Tgf-α is required for tumor growth and cancer cell survival. (A) Comparison of the average number of hemorrhagic angiogenic islets dysplasias 
in wild-type (wt/wt), waved-1 heterozygous (wt/wa1), and waved-1 homozygous (wa1/wa1) 9-week-old RT2 mice; waved-1 is a loss-of-function allele of Tgf-α. 
(B-C) Comparison of the average (B) tumor burden or (C) tumor number in wild-type (wt/wt), waved-1 heterozygous (wt/wa1), and waved-1 homozygous 
(wa1/wa1) 14-week-old RT2 mice. (D) Western blot analysis of Tgf-α protein expression in total protein extracts from pools of 5 wild-type or 5 waved-1 
mutant tumors. (E) Average percentage of dividing tumor cells (phospho-histone H3-positive) in wild-type or waved-1 mutant tumors at 14 weeks of age. 
(F) Average vessel density (ratio of Meca-32 stained area to total section area) in wild-type or waved-1 mutant tumors at 14 weeks of age. (G) Average 
percentage of apoptotic tumor cells (TdT-mediated dUTP-biotin nick end-labeling [TUNEL] positive) in wild-type or waved-1 mutant tumors at 14 weeks 
of age. (H-I) Representative micrograph of a (H) wild-type or a (I) waved-1 mutant tumor stained with anti-digoxigenin following the TUNEL procedure 
(green) and DAPI (blue) (200x); panels are representative of 12 wild-type and 16 waved-1 RT2 tumors dissected from at least 5 independent mice of each 
genotype. (N = number of independent mice [A-C] or tumor fields [D-F] analyzed per genotype—1 to 2 fields per tumor). *P < 0.001.132    Genes & Cancer / vol 1 no 2 (2010)
defects in angiogenic switching observed at an earlier stage 
of disease progression (i.e., that Hb-egf mutant mice present 
a decreased tumor load because they develop fewer angio-
genic precursor lesions, not because of a defect per se in 
tumor cell growth or apoptosis).
Distinct pools of Egfr activity in PNET cancer cells and in 
perivascular cells. To better understand the distinct histopath-
ologic phenotypes observed in tumors of Tgf-α versus Hb-
egf loss-of-function mutants and to relate them to the effects 
seen  in  EGFR  inhibitor-treated  tumors,  we  sought  to 
Figure 5. Hb-egf contributes to the angiogenic switch and neovascularization of PNET tumors. (A) Comparison of the average number of hemorrhagic 
angiogenic islets in wild-type (wt) and Hb-egf mutant (Hb) 9-week-old RT2 mice. (B-C) Comparison of the average (B) tumor burden or (C) tumor 
number in wild-type and Hb-egf mutant 14-week-old RT2 mice. (D) Western blot analysis of Hb-egf protein expression in total protein extracts from 
pools of 5 wild-type or 5 Hb-egf mutant tumors. (E-F) Average percentage of (E) dividing tumor cells (phospho-histone H3 positive) or (F) apoptotic 
cells (TdT-mediated dUTP-biotin nick end-labeling [TUNEL] positive) in wild-type or Hb-egf mutant tumors at 14 weeks of age. (G) Average vessel density 
(ratio of Meca-32 stained area to total section area) in wild-type or Hb-egf mutant tumors at 14 weeks of age. (H-I) Representative micrographs of (H) 
wild-type or (I) Hb-egf mutant RT2 tumors stained with Meca-32 (red) and DAPI (blue) (200x); panels are representative of 20 wild-type and 18 Hb-egf 
RT2 tumors dissected from at least 5 independent mice of each genotype. (N = number of independent mice [A-C] or tumor fields [E-G] analyzed per 
genotype; 1-2 fields per tumor.) *P < 0.001. **P < 0.01. ***P < 0.05.Parallel activation of Egfr in cancer cells and pericytes / Nolan-Stevaux et al.  133
identify the cell types expressing Egfr and its ligands inside 
tumors. To this end, we separated the different constituent 
cell types found in wild-type tumors by flow cytometry, by 
labeling endothelial cells with an anti-CD31 antibody, peri-
vascular cells with an anti-PDGFR-β antibody, and immune 
cells with anti-GR1 and anti-CD11b antibodies. The vari-
ous cellular fractions were represented as follows: tumor 
cells/other cells, 88.5%; immune cells, 2.8%; endothelial 
cells,  1.4%;  pericytes,  1.8%;  and  gated-out,  5.5%. Total 
RNA isolated from these fluorescence-activated cell sorting 
(FACS)–sorted cell populations was converted to cDNA 
and  analyzed  by  quantitative  RT-PCR  to  assess  the 
expression patterns of Tgf-α, Hb-egf, and Egfr alongside 
cell-type specific control genes that establish the purity of 
the sorted cell populations. Relative expression levels of the 
control genes indicated that the FACS procedure yielded 
very pure cellular fractions, with minimal cross-contamina-
tion of the specific markers in the other sorted populations 
(Fig. 6A—TC, EC, PC, and IC control panels). The analysis 
reveals that Egfr is expressed in cancer cells, is not detected 
in tumor endothelial cells or infiltrating immune cells, but, 
surprisingly, is highly enriched in PDGFR-β positive cells 
that predominantly comprise endothelium-associated peri-
vascular cells in the PNET tumors of RT2 mice.
38 Hb-egf is 
Figure 6. Distinct pools of Egfr activity in cancer cells and perivascular cells. (A) Expression of cell-type defining genes m-Insulin1, Pecam1, Pdgfr-α, Ptprt, and 
of Egfr, Hb-egf, and Tgf-α in sorted cells from RT2-derived PNET tumors (NS = nonsorted cells; EC = endothelial cells; PC = pericytes; IC = immune cells; 
TC = unlabeled tumor cells) relative to the expression detected in nonsorted cells (NS = 1). Gene expression in each cellular fraction was normalized to 
levels of Cyclophilin. (B) Comparison of the relative in vitro growth of 2 RT2 tumor-derived cancer cell lines (BTC3 and BTC4) following 3 days of treatment 
with DMSO or gefitinib 5 μM. (C) Anti-NG2 staining (red) reveals pericytes (200x). (D) Co-localization of NG2 (red) with phospho-EGFR Tyr1068 
(pEgfr, green) (200x). (E) High magnification confocal localization reveals expression of phospho-Egfr (green) in pericytes expressing NG2 (red) (1600x). 
(F) High-magnification confocal localization of phospho-Egfr (green) and an endothelial specific marker (Meca-32, red) does not indicate Egfr activity in 
tumor endothelial cells (2,000x). (C-H) Micrographs are representative of multiple fields of more than 10 tumors from at least 3 independent RT2 mice.134    Genes & Cancer / vol 1 no 2 (2010)
highly enriched in tumor endothelial cells and perivascular 
cells and, to a lesser extent in cancer cells, whereas Tgf-α 
appears exclusively enriched in the unlabeled cancer cell 
fraction (Fig. 6A).
The presence of 2 distinct pools of Egfr mRNA, one in 
cancer cells and one in perivascular cells, led us to explore 
Egfr function in both of these cellular compartments. We 
first  confirmed  that  Egfr  is  functionally  activated  and 
required inside the cancer cells, as we were able to detect 
the phosphorylated form of Egfr (pEgfr) in cancer cells in 
vivo (Supplementary Fig. S4A). We then subjected RT2 
tumor-derived cancer cell lines (BTC3 and BTC4) to treat-
ment with the gefitinib EGFR inhibitor, after profiling of 
Egf family ligands and Erbb receptors in these BTC cell 
lines revealed that they express the same family members in 
vitro (Egfr, Tgf-α, and Hb-egf) as the cognate tumors do in 
vivo (Supplementary Figs. S4 B and C). We found that gefi-
tinib has a significant impact on the growth of BTC lines in 
vitro (Fig. 6B) as well as on tumor growth in vivo (Fig. 1F), 
with the cell culture result substantiating the conclusion 
that Egfr signaling is involved in stimulating the cancer 
cells in a cell autonomous manner, consistent with the phe-
notype of Tgf-α mutant RT2 mice.
We then explored the possible function of Egfr inside 
tumor vessel-associated pericytes. First, we were able to   
co-localize pEgfr with NG2, a pericyte marker, indicating 
that Egfr is phosphorylated and activated in a subset of 
tumor pericytes in vivo (Figs. 6 C-F). Given the close prox-
imity of pericytes with endothelial cells, we sought to assess 
the possibility that pEgfr was actually expressed in endo-
thelial  cells  and  mistakenly  co-localized  with  pericytes. 
Therefore,  we  stained  tumor  sections  for  pEgfr  and  the 
Meca-32  endothelial  cell  marker,  which  revealed  that 
pEgfr-positive cells and endothelial cells are adjacent but 
clearly distinct cell types (Figs. 6 G-H).
These  analyses  reveal  that  two  cellular  compartments 
express active Egfr inside these PNET tumors: cancer cells 
and pericytes. Similarly, ligand expression is compartmental-
ized: Tgf-α is exclusively parenchymal, whereas Hb-egf is 
expressed by the tumor parenchyma as well as the tumor 
stroma. These observations, coupled with the distinct and 
separable  phenotypes  observed  in  the  Tgf-α  and  Hb-egf 
mutants, implicate two parallel Egfr intercellular signaling 
circuits in these PNET tumors: one circuit involves mem-
brane-tethered  Tgf-α  that  signals  in  autocrine/juxtacrine 
fashion to Egfr expressed as well on cancer cells, thereby 
enhancing  cancer  cell  survival,  while  the  second  circuit 
involves Hb-egf expressed in multiple cell types, which sig-
nals to Egfr expressed on pericytes of the tumor vasculature.
Hb-egf activates Egfr in pericytes and enhances pericytes 
coverage  of  the  tumor  endothelium.  Because  Hb-egf  is  a 
potent mitogen for smooth muscle cells and is able to trig-
ger smooth muscle cell migration toward endothelial cells 
in vitro,
39,40 we pursued the hypothesis that Hb-egf activates 
Egfr  signaling  inside  perivascular  cells  and  stimulates 
pericyte  coverage  of  the  tumor  vasculature  in  vivo.  We 
tested  this  hypothesis  by  staining  the  tumor  vasculature 
with an endothelial marker (Meca-32) and a mature peri-
cyte marker (Desmin) to determine the relative pericytic 
coverage  of  the  tumor  vasculature  comparing  control 
tumors, erlotinib-treated tumors, and Hb-egf mutant tumors.
Congruent with this hypothesis, tumors treated with an 
EGFR  inhibitor  displayed  a  significant  ~27%  decrease   
in  mature  pericyte  coverage  of  the  tumor  endothelium   
(Fig. 7A). Pericyte coverage was decreased by ~32% in Hb-
egf mutant angiogenic islets (Fig. 7B), by ~24% in large 
tumors (Fig. 7C), and by ~41% in small tumors (ø ≤ 3 mm—
Fig.  7D)  from  Hb-egf  mutant  RT2  mice  (representative 
tumor panels from each genotype, Figs. 7 E-F). Analysis of 
the unaffected exocrine compartment of the tumor-bearing 
pancreas of RT2, Hb-egf−/− mice revealed no effect on ves-
sel density (data not shown) or on pericyte coverage of the 
normal  tissue  vasculature  (Fig.  7G),  indicating  that  the 
effect on pericyte coverage is specific to the tumor vascula-
ture. Moreover, Tgf-α mutant tumors showed no decrease in 
vessel density (Fig. 4F) or in pericyte coverage (data not 
shown), demonstrating that EGF family ligands are limiting 
for specific and distinct pathological functions in vivo.
Finally, we observed the near-complete disappearance of 
perivascular  phospho-Egfr  staining  in  Hb-egf  mutant 
tumors (Figs. 7 H and I), thus further supporting our hypoth-
esis that Hb-egf is the key limiting ligand involved in Egfr 
signaling inside perivascular cells.
Mesenchymal Hb-egf mediates Egfr activation and functions 
in tumor-associated pericytes. Given that Hb-egf is expressed 
in tumor cells as well as in tumor endothelial cells (Figs. 8 
A and B) and pericytes (Fig. 6A), we sought to establish 
which reservoir of Hb-egf was responsible for mediating 
the proangiogenic activity of Egfr. To this end, we obtained 
an Hb-egf null cancer cell line from an Hb-egf mutant RT2-
derived tumor and implanted it orthotopically in the pan-
creas of 8 syngeneic wild-type mice or 8 Hb-egf mutant 
mice (see schematic in Fig. 8C). This Hb-egf mutant cell 
line produced tumors in both genetic backgrounds, but the 
pericyte  coverage  of  the  tumor  neovasculature  was 
decreased  by  ~24%  in  tumors  recovered  from  Hb-egf 
mutant hosts compared to tumors recovered from wild-type 
hosts (Fig. 8D). The vascular density of tumors grown in 
the Hb-egf mutant hosts was also decreased by ~20% com-
pared to tumors grown in wild-type hosts (data not shown). 
Moreover,  perivascular  Egfr  phosphorylation,  while  less 
prominent in the orthotopically transplanted tumors than in 
spontaneous tumors arising in RT2 mice, was nonetheless 
almost entirely eliminated in orthotopic tumors grown in 
Hb-egf mutant hosts (Figs. 8 E and F).
Together, these results indicate that the mesenchymal 
pool  of  Hb-egf  retained  in  wild-type  syngeneic  hosts  is 
responsible for the in vivo activation of Egfr signaling in 
perivascular cells and for the enhancement of tumor angio-
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Discussion
Successful anticancer therapy with EGFR inhibitors is cur-
rently  predicated  on  uncovering  genetic  and  epigenetic 
factors that identify tumors addicted to Egfr signaling for 
their malignant phenotype. To date, mutations in the EGFR 
kinase  domain
12  and  chromosomal  amplification  of  the 
EGFR receptor
17 are the only clinically validated genetic 
Figure 7. Contributions of Hb-egf and Egfr to pericyte coverage of the tumor neovasculature. (A-D, G) Pericyte coverage of the endothelium as a 
percentage of total vessel area in different stages and genetic contexts. (A) Comparison of vehicle- and erlotinib-treated tumors from 14-week-old 
RT2 mice. (B) Comparison of angiogenic islets from 9-week-old wild-type versus Hb-egf mutant RT2 mice. (C) Comparison of wild-type versus Hb-egf 
mutant tumors from 14-week-old RT2 mice. (D) Comparison of small wild-type and Hb-egf mutant tumors (ø < 3 mm) from 14-week-old RT2 mice. (G) 
Comparison of wild-type and mutant exocrine pancreas. (E-F) Representative staining of angiogenic microvessels (with Meca-32; red) and pericytes (with 
Desmin; green) (400x) in small (E) wild-type and (F) Hb-egf mutant tumors. (N = number of fields of tumors or angiogenic islet analyzed per genotype 
or treatment group; 1-2 fields per lesion analyzed.) (H-I) Representative staining of a pericyte marker (NG2; red) and activated phospho-Egfr (green) in 
tumors from (H) wild-type or (I) Hb-egf mutant RT2 mice. Micrographs are representative of several fields of more than 10 RT2 tumors from at least 3 
independent mice of each genotype. *P < 0.05. **P < 0.01. ***P < 0.001.136    Genes & Cancer / vol 1 no 2 (2010)
factors with positive predictive value of EGFR inhibitor sen-
sitivity, whereas the presence of a Kras mutation is a genetic 
factor with negative predictive value.
41 The low frequency 
of objective clinical responses in patients carrying wild-
type, nonamplified alleles of EGFR has raised the legiti-
mate  question  as  to  whether  wild-type  EGFR  is  even 
oncogenic.
8 However, clinical responders with wild-type 
EGFR do exist, and the frequency of patients displaying 
stable disease in response to EGFR inhibitors far exceeds 
the frequency of EGFR kinase domain mutations.
12
Our study in a mouse model of pancreatic neuroendo-
crine  carcinogenesis  demonstrates  that  tumors  harboring 
wild-type diploid alleles of Egfr can be sensitive to EGFR 
inhibitors, and thus wild-type Egfr is tumor promoting in 
some tumor types. Notably, however, the significant slow-
ing of tumor growth we observe is not regarded as an objec-
tive response in a clinical setting where tumor shrinkage is 
expected. Nonetheless, our results, combined with observa-
tions  that  (1)  EGFR  levels  correlate  with  the  malignant 
grade of endocrine tumors,
42 (2) EGFR inhibitors increase 
apoptosis in a human PNET cell line,
42 and (3) phosphory-
lated  EGFR  is  detected  in  most  human  neuroendocrine 
tumors,
24  suggest  that  some  PNET  patients  may  benefit 
from anti-EGFR therapy. Our results also argue that the 
detection  of  phosphorylated  EGFR  in  conjunction  with 
upregulated expression of an EGF family ligand, particu-
larly TGF-α, a known prognostic factor of poor disease out-
come in numerous cancer types,
18 may prove an informative 
criterion of patient stratification when evaluating response 
to anti-EGFR therapy. Furthermore, TGF-α expression was 
strongly  correlated  with  EGFR  inhibitor  sensitivity  and 
apoptosis induction upon EGFR inhibitor treatment in a 
panel  of  42  NSCLC  cell  lines,  only  2  of  which  carried 
EGFR mutations.
43 Interestingly, while we anticipated that 
upregulated TGF-α in the cancer cells would act as a mito-
genic growth factor via autocrine/juxtacrine signaling to 
Egfr expressed in those cancer cells, both genetic and phar-
macological  interference  with  this  signaling  axis  caused   
an increase in the frequency of apoptosis, not a reduction   
in cancer cell proliferation. The basis both of mitogenic 
stimulation in these PNET tumors and the mechanisms by 
which  TGF-α  acts  as  a  survival  factor  warrants  future 
investigation.
Hb-egf activates Egfr in pericytes of the tumor vasculature. 
In this study, we observed a reproducible decrease in the 
microvascular density of tumors treated with EGFR inhibi-
tors or genetically depleted of the Hb-egf ligand. Studies to 
date have described 2 proangiogenic mechanisms for EGFR 
signaling: first, some tumor cells induce critical angiogenic 
factors,  such  as  VEGF-A,  in  an  EGFR-dependent  man-
ner
44,45; second, direct EGFR activation inside endothelial 
cells has been reported in several subcutaneous and ortho-
topic  xenograft  tumor  models
46,47  and  found  to  support 
endothelial cell survival and tumor growth.
48 By contrast, in 
the spontaneous RT2 model of mouse PNET as well as in 
one anecdotal human PNET sample (data not shown), we 
found  that  endothelial  cells  did  not  express  EGFR;  in 
Figure  8.  Mesenchymal-derived  Hb-egf  activates  Egfr  inside  tumor 
pericytes.  (A-B)  Co-staining  of  Hb-egf  staining  (red)  and  Meca-32 
(endothelial cell marker; green) by confocal microscopy (2,520x) reveals 
both  cancer  cell  expression  (red)  and  endothelial  cell  co-localization 
(yellow) of Hb-egf. (C) Schematic description of the orthotopic transplant 
experiment aimed at assessing the contribution of mesenchymal-derived 
Hb-egf  to  the  angiogenic  phenotype  of  pancreatic  neuroendocrine 
tumorigenesis  (PNET)  tumors.  (D)  Comparison  of  pericyte  coverage 
of  the  tumor  neovasculature  in  wild-type  (wt)  versus  Hb-egf  mutant 
(Hb–/–) hosts. **P < 0.0005. (Number of tumors analyzed for each host 
genotype: N
wt = 11, N
Hb = 12.) (E-F) Representative staining of tumors 
for nuclei (DAPI; blue), NG2 (pericyte marker; red), and pEgfr (green) 
illustrating that the readily detectable pEgfr signal localized to pericytes 
in wild-type hosts (white arrows) (E) disappears in Hb-egf mutant hosts 
(F). pEgfr can be detected in cancer cells but at many-fold lower levels 
than in perivascular cells (see Supplementary Fig. S4). Micrographs are 
representative of 2 fields of 12 and 11 tumors obtained from wt or Hb-egf 
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addition, we did not detect a decrease in Vegf-a expression 
following gefitinib treatment (data not shown). Instead, we 
uncovered a novel in vivo mechanism whereby Hb-egf → 
Egfr signaling contributes to tumor angiogenesis: Egfr is 
directly activated inside tumor-associated pericytes, a mes-
enchymal cell type physically associated with microvascu-
lar  endothelial  cells,  which  supports  endothelial  cell 
function and integrity.
49 We observe that Hb-egf secreted by 
cell types of the tumor stroma, either the pericytes them-
selves or the tumor endothelial cells, contributes to the peri-
cyte  coverage  of  the  tumor  endothelium.  Our  results 
corroborate an earlier in vitro study in which HUVEC endo-
thelial cells were shown to express HB-EGF and promote 
the migration, in a trans-well migration assay, of EGFR-
positive smooth muscle cells toward endothelial cells in an 
HB-EGF/EGFR-dependent manner,
40 as well as an in vivo 
study from the same group describing decreased pericyte 
coverage  of  the  tumor  microvasculature  in  transplanted 
tumors following gefitinib treatment.
50
Two  questions  relating  to  the  interplay  between   
pericytes and endothelial cells in vivo arise from our work: 
first, what mechanism underlies the decrease in Desmin-
positive pericyte coverage following Egfr signaling inhibi-
tion (consequent to inhibitor treatment or genetic ablation 
of Hb-egf), and second, how does a reduction in pericyte 
coverage translate into a decreased density of the tumor 
microvasculature?
In  regard  to  the  first  question,  induction  of  Desmin 
expression appears to define the final step of pericyte dif-
ferentiation, which involves intimate interaction with endo-
thelial cells.
38 Perivascular cells expressing other markers, 
such as Pdgfr-β (the earliest marker of pericyte differentia-
tion) or NG2 plus α-SMA, define pools of partially differ-
entiated  perivascular  precursor  cells  from  which  fully 
differentiated  Desmin-positive  cells  eventually  emerge.
38 
Following treatment with erlotinib, or in Hb-egf mutant 
lesions, we observe a more pronounced reduction in peri-
vascular  coverage  by  fully  differentiated  Desmin- 
positive  cells  as  compared  to  NG2-positive  precursor 
(~30% decrease in Desmin-positive cell coverage versus 
~15% decrease in NG2-positive cell coverage—Figs. 7 C 
and D and data not shown). These results suggest that, when 
Egfr signaling is interrupted in perivascular precursor cells, 
as evidenced by the loss of pEgfr staining in the precursor 
NG2-positive pericytes of Hb-egf mutant tumors (Figs. 7 H 
and I), either those partially differentiated Desmin-negative 
pericyte precursors do not mature into fully differentiated 
Desmin-positive pericytes in the first place or such mature 
Desmin-positive  pericytes  are  not  stably  maintained  in 
association with the tumor vasculature.
As to how a pericyte coverage defect translates into a 
microvessel density decrease, it is established that interrup-
tion of endothelial/pericyte interaction with Pdgfr-β inhibitors 
indirectly affects the tumor microvasculature by catalyzing 
endothelial cell apoptosis
38 and sensitizes the endothelium 
to additional stresses such as low-dose metronomic chemo-
therapy
51 or Vegf receptor inhibition.
52 This indirect effect 
on the tumor endothelium likely stems from the fact that 
pericytes produce a number of growth factors that support 
endothelial  cell  growth  and  survival.
49  Much  like  with 
PDGFR inhibitors, EGFR inhibitors do not affect pericyte 
coverage or the homeostasis of normal tissue vessels, sug-
gesting that other mechanisms preserve pericyte coverage 
in static, nonangiogenic endothelium.
In conclusion, this study (1) adds new support to the link 
between the expression of EGF family growth factors and 
tumor sensitivity to EGFR inhibitors in the context of wild-
type EGFR; (2) demonstrates that EGF family ligands are 
not functionally redundant during tumorigenesis but play 
simultaneous, specific, and discrete pathological functions 
inside different cellular compartments of the same tumor; 
and (3) describes a novel in vivo proangiogenic mechanism 
driven by Egfr signaling inside pericytes and mediated by 
mesenchyme-derived Hb-egf. Finally, the parallel signaling 
axes  we  describe  suggest  that  in  some  contexts,  EGFR 
inhibitors  may  show  combinatorial  benefit  with  VEGF 
pathway  inhibitors,  whereby  the  EGFR  inhibitor  both 
impairs cancer cell survival and reduces pericyte coverage, 
with the latter rendering the tumor endothelium more sensi-
tive to VEGFR inhibition.
Materials and Methods
Mouse Strains and Genotyping
All mouse strains were previously described.
22,29,36,53 The 
waved-1 mice (B6.Cg-Tgfa
wa1/J strain) were obtained from 
Jackson Laboratory (Bar Harbor, ME) and were maintained 
in a pure C57BL/6J background; Hb-egf mutant mice were 
backcrossed for 10 generations in the C3HeB/FeJ back-
ground (we used this background because Hb-egf loss of 
function is nonviable in a pure C57BL/6J background). The 
RT2 transgene has been backcrossed for multiple genera-
tions (N > 60) in a pure C57BL/6J or a pure C3HeB/FeJ 
background. To genotype waved-1 mice, we distinguished 
heterozygous from homozygous mice based on the wavy 
hair phenotype. Wild-type Hb-egf genotyping: HB3 primer 
ccaggtataaataggacatttgagga and HB4 primer ttgcaggaagac
tgtgtcac (~400-bp band). Mutant Hb-egf genotyping: HB4 
primer and ND2 primer tgctctttactgaaggctctttac at 0.5 μM 
(~300-bp band). All studies were conducted in compliance 
with University of California Institutional Animal Care and 
Use Committee (IACUC) guidelines.
Mouse Treatment with EGFR Inhibitors
Compounds  were  obtained  from  commercial  sources, 
reduced to a powder, and resuspended in a vehicle solution 
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NaCl) and orally delivered to mice in once-daily gavages at 
the following dosage: gefitinib (80 mg/kg), erlotinib (80 
mg/kg), and CI-1033 (80 mg/kg). Mice were treated from 
11 to 14 weeks of age in intervention trials, 6 to 9 weeks of 
age in prevention trials, and 12 to 16 weeks of age in regres-
sion trials. Mice were sacrificed 2 to 4 hours after the last 
oral delivery of drugs.
Orthotopic Transplant Experiment
The pancreases of 8 syngeneic (C3H/HeJ) wild-type hosts 
(4 males and 4 females) obtained from Jackson Laboratory 
and of 8 Hb-egf mutant hosts (4 males and 4 females) were 
injected  orthotopically  with  250,000  BTC  Hb−/−  cells 
resuspended in 50 μL of phosphate-buffered saline (PBS)/
Growth  Factor  Reduced  Matrigel™  (1:1)  (#356231,  BD 
Biosciences,  Franklin  Lakes,  NJ)  using  a  28G1/2-gauge 
insulin syringe (BD #329461). After 11 weeks, following 
the death of a control animal injected with wild-type BTC 
cells,  tumors  were  recovered  from  these  mice  and 
analyzed.
Isolation of Pancreatic Islets
Islets  from  10-week-old  wild-type  C57BL/6J  mice  were 
pooled to generate normal islet (NI) extracts. White islets 
from 6- to 8-week-old RT2 mice were used to generate 
hyperplastic  islets  (HI)  extracts.  Red  islets  from  6-  to 
8-week-old RT2 mice were used to generate angiogenic 
islet (AI) extracts. Islet tumor (IT) extracts were generated 
from islet tumors dissected from 14-week-old mice. The 
method for isolating islets of Langerhans from murine pan-
creas was previously described.
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Quantitative PCR
Total RNA was prepared using RNeasy Mini™ (Qiagen, 
Valencia, CA) following the manufacturer’s recommenda-
tions. DNAse treatment and RNA cleanup were performed 
with the DNA-Free RNA Kit™ (Zymo Research, Orange, 
CA).  cDNA  synthesis  was  performed  using  qScript™ 
cDNA supermix (Quanta BioScience, Gaithersburg, MD). 
Quantitative  real-time  PCR  was  performed  using  the   
following TaqMan® assays (Applied Biosystems, Foster 
City, CA) or specifically designed assays: Mm00433023_
m1  (Egfr/Erbb1),  Mm00658541_m1  (Erbb2),  For:
cgg   gacc  caccaaggtatc/Rev:ttggtgctcagagcagatgg/
Probe:fam-tcatcaagagagcgagtgggcctgg-bhq1  (Erbb3),  For:
gctgctcaggaccaaaggac/Rev:agtaacgcaggctccactgtc/
Probe:fam-ctgactgctttgcctgcatgaacttca-bhq1  (Erbb4), 
Mm00438696_m1  (Egf),  Mm00437583_m1  (Areg), 
Mm00504344_m1  (Epg),  Mm00446231_m1  (Tgfa), 
Mm00514794_m1  (Epr),  Mm00432137_m1  (Btc), 
Mm00439307_m1 (Hb-egf/Dtr), Mm00626552_m1 (Nrg-
1),  For:aatggaggcgtgtgctactaca/Rev:ccgaagaatccgtttggaca/
Probe:fam-cgaaggcatcaaccaactctcctgca-bhq1 (Nrg-2a), For:
tggaggcgtgtgctactacatc/Rev:cccggtgtatcccacagg/Probe: 
fam-aaggcatcaaccaactctcctgcaagtg-bhq1 (Nrg-2b), Mm004-
35367_m1 (Nrg-3), Mm00446254_m1 (Nrg-4), Hs01076092_
m1 (Human EGFR), Hs00961131_m1 (Human HBEGF), 
Hs00177401_m1  (Human  TGF-α),  For:ctcatctggaatttcgccga/
Rev:ggcgagtgaagatccccttc/Probe:fam-cgaaccagtcaccgct 
gagagtaatcg-bhq1 (mGus), Mm00435546_m1 (PDGFR-β), 
Mm00476702_m1  (Pecam1/CD31),  and  Mm00448463_
m1 (Ptprt/CD45). The IDT assays were obtained from Inte-
grated  DNA  Technologies  (Coralville,  IA).  All  assays 
amplified a specific amplicon from a testis, brain, or embry-
onic mouse cDNA library (#10667012, Invitrogen, Carls-
bad,  CA).  qPCR  reactions  were  performed  on  an 
ABI7900HT Sequence Detection System. Ct values were 
determined  and  subtracted  to  obtain  the  ΔCt  [ΔCt  =   
Ct (test locus) – Ct (control locus)]. Relative fold difference 
was calculated as 2Δ
Ct × 100.
Western Blot Analysis
The following antibodies were used: goat anti-TGF-α (0.2 
μg/mL [R&D Systems, Minneapolis, MN, #AF-239-NA]), 
goat  anti-HB-EGF  (0.2  μg/mL  [R&D  Systems  #AF-
259-NA]), rabbit anti-SV40 large T antigen (1:10,000),
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rabbit anti-EGFR (1:200 [Santa Cruz Biotechnology, Santa 
Cruz, CA, #sc-03]), mouse anti-phospho-EGFR (1:1,000 
[Cell Signaling, Danvers, MA, #2236]), rabbit anti-MEK1/2 
(1:2,000  [Cell  Signaling  #9122]),  rabbit  anti-phospho-
MEK1/2 (1:1,000 [Cell Signaling #9154]), rabbit anti-Akt 
(1:2,000 [Cell Signaling #9272]), rabbit anti-phospho-Akt 
(1:1,000  [Cell  Signaling  #9271]),  mouse  anti-β-actin 
(1:10,000 [Sigma-Aldrich, ST. Louis, MO, #A-5441]). Rel-
ative band quantifications were obtained using Photoshop 
7.0 software.
Histological Analysis, Immunochemistry, and 
Immunofluorescence
All tumors analyzed were considered “islet tumors” stage 
lesions with a diameter >1 mm. Tumors were snap-frozen 
in  liquid  nitrogen  upon  dissection  and  arrayed  in  OCT   
(Tissue-Tek  #4583).  Sections  10  μm  thick  were  briefly 
fixed in ice-cold acetone or paraformaldehyde 3.2% for 10 
min or nonfixed depending on the antibody used. Sections 
stained with the anti-pEGFR antibodies were subjected to 
an  antigen-unmasking  procedure  (Vector  Laboratories, 
Burlingame,  CA,  #H-3300).  For  use  of  mouse  primary   
antibodies, slides were incubated with MOM™ kit reagent 
(Vector  Laboratories  #BMK-2202).  Primary  antibodies 
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were used: rat anti–Pan Endothelial Cell Antigen antibody 
(Meca-32  clone,  BD/Pharmingen,  San  Diego,  CA, 
#553849), goat anti-HB-EGF (10 μg/mL [R&D Systems 
#AF-259-NA]),  mouse  anti-phospho-EGFR1-Tyr1068 
(1:100  [Cell  Signaling  #2236]),  rabbit  anti-phospho-
EGFR2-Tyr845 and Tyr992 (1:100 [Cell Signaling #2231, 
#2235]), rabbit anti-NG2 (1:200 [Millipore, Billerica, MA, 
#AB5320]),  rabbit  anti-glucagon  (1:4,000  [Millipore 
#4030-01F]), rat anti-PDGFR-β (1:100 [eBioscience, San 
Diego,  CA,  #14-1402-81]),  mouse  anti-Desmin  (1:100 
[Dako, Glostrup, Denmark, #M0760]), and mouse antihu-
man  CD34  (1:100  [BD  Pharmingen,  San  Diego,  CA, 
#555820]). Fluorochrome-conjugated antibodies were used 
as secondary antibodies (1:200 [Jackson ImmunoResearch, 
West Grove, PA]). Images of H&E- and DAB-stained sec-
tions were obtained with a Zeiss AxioImager brightfield 
microscope, fluorescent images were obtained with a Zeiss 
AxioScope2  widefield  microscope,  and  confocal  images 
were obtained with a Leica SL confocal microscope.
Vessel Density and Vessel Coverage Analysis
FITC-lectin  labeling  of  the  vasculature  was  previously 
described.
56 FITC-positive vessels were counted manually, 
or vessel area (labeled with Meca-32 antibody) and pericyte 
area (labeled with anti-Desmin antibody) were analyzed and 
percentage of pixel overlap measured with the MetaMorph
® 
software (angiogenesis application). For each condition or 
genotype, 2 pictures were taken for each tumor lesion ana-
lyzed, one at the center and one at the periphery of the tumor. 
For  vessel  density  analysis,  pictures  were  taken  at  200x 
magnification. Each picture represents ~0.4 mm
2 or about 
~8% of the average surface of RT2 tumors (2.5 mm in ø ~ 5 
mm
2). For pericyte coverage analysis, pictures were taken at 
400x magnification, and each picture represents ~0.1 mm
2 
or about ~2% of the average surface of RT2 tumors.
Apoptosis and Proliferation Assays
TUNEL and BrdU detection assays were performed as pre-
viously described.
57 A rabbit anti-Phospho-Histone H3 anti-
body (1:100 [Upstate/Millipore #06-570]) was also used to 
detect cell divisions in vivo. Positive nuclei were counted 
using the MetaMorph® software (cell count application).
In Vitro BTC Cell Growth Assay
In total, 300,000 beta-TC3 or beta-TC4 cells were plated on 
day 0 in 6-well culture dishes. A gefitinib solution (5 mM 
gefitinib dissolved in DMSO) was diluted 1,000x in the 
Dulbecco’s  modified  Eagle’s  medium  (DMEM)  high- 
glucose cell culture media (Gibco, Carlsbad, CA, #11971), 
supplemented with 0.5% fetal calf serum. DMSO diluted 
1,000x was used as control. The media were replaced every 
24 h. After 72 h, cells were counted.
Flow Cytometry
Tumors were excised from 14-week-old RT2 mice; inflam-
matory cells, endothelial cells, pericytes, and tumor cells 
were collected by FACS sorting as previously described.
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